Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells

Cytotherapy

Volumn 18, Issue 4, 2016, Pages 570-580

  Pinho, Mariana Pereira ^a   Sundarasetty, Bala Sai ^b   Bergami Santos, Patricia Cruz ^a   Steponavicius Cruz, Karen ^a   Ferreira, Adilson Kleber ^a   Stripecke, Renata ^b   Barbuto, José Alexandre M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cancer vaccines; Cell fusion; Dendritic cells; Hybrid cells; Immunotherapy

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; CANCER VACCINE; HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROFUSION (CELL); ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYBRID CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL; ANTIGEN PRESENTATION; CELL CULTURE; CELL FUSION; CELLULAR IMMUNITY; COCULTURE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTIGEN PRESENTATION; CANCER VACCINES; CELL FUSION; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYBRID CELLS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84960194118     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.01.005     Document Type: Article

References (54)

1. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5(4):296-306. 10.1038/nri1592.
2. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96(9):3102-3108.
3. Bubenik J. Genetically engineered dendritic cell-based cancer vaccines (review). Int J Oncol 2001, 18(3):475-478.
4. Zhou Y., Bosch M.L., Salgaller M.L. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002, 25(4):289-303.
5. Mosca P.J., Lyerly H.K., Clay T.M., Morse M.A. Dendritic cell vaccines. Front Biosci 2007, 12:4050-4060.
6. Anguille S., Van Tendeloo V.F., Berneman Z.N. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012, 26(10):2186-2196. 10.1038/leu.2012.145.
7. Kotera Y., Shimizu K., Mule J.J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001, 61(22):8105-8109.
8. Milazzo C., Reichardt V.L., Muller M.R., Grunebach F., Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003, 101(3):977-982. 10.1182/blood-2002-04-1273.
9. Strome S.E., Voss S., Wilcox R., Wakefield T.L., Tamada K., Flies D., et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002, 62(6):1884-1889.
10. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4(5):594-600.
11. Cathelin D., Nicolas A., Bouchot A., Fraszczak J., Labbe J., Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy: what's next?. Cytotherapy 2011, 13(7):774-785. 10.3109/14653249.2011.553593.
12. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997, 3(5):558-561.
13. Jantscheff P., Spagnoli G., Zajac P., Rochlitz C.F. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother 2002, 51(7):367-375. 10.1007/s00262-002-0295-1.
14. Yang J., Shen M.H. Polyethylene glycol-mediated cell fusion. Methods Mol Biol 2006, 325:59-66. 10.1385/1-59745-005-7:59.
15. Scott-Taylor T.H., Pettengell R., Clarke I., Stuhler G., La Barthe M.C., Walden P., et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 2000, 1500(3):265-279.
16. Kawada M., Ikeda H., Takahashi T., Ishizu A., Ishikura H., Katoh H., et al. Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth in vivo. Int J Cancer 2003, 105(4):520-526. 10.1002/ijc.11120.
17. Kim G.Y., Chae H.J., Kim K.H., Yoon M.S., Lee K.S., Lee C.M., et al. Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo. Biosci Biotechnol Biochem 2007, 71(1):215-221. 10.1271/bbb.60517.
18. Lespagnard L., Mettens P., Verheyden A.M., Tasiaux N., Thielemans K., van Meirvenne S., et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 1998, 76(2):250-258.
19. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004, 10(14):4699-4708. 10.1158/1078-0432.CCR-04-0347.
20. Barbuto J.A., Ensina L.F., Neves A.R., Bergami-Santos P., Leite K.R., Marques R., et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004, 53(12):1111-1118. 10.1007/s00262-004-0551-7.
21. Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T., Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001, 50(7):337-344.
22. Galea-Lauri J., Darling D., Mufti G., Harrison P., Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002, 51(6):299-310. 10.1007/s00262-002-0284-4.
23. Kao J.Y., Zhang M., Chen C.M., Chen J.J. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 2005, 101(2):154-159. 10.1016/j.imlet.2005.05.006.
24. Shimizu K., Kuriyama H., Kjaergaard J., Lee W., Tanaka H., Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 2004, 27(4):265-272.
25. Yasuda T., Kamigaki T., Nakamura T., Imanishi T., Hayashi S., Kawasaki K., et al. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Oncol Rep 2006, 16(6):1317-1324.
26. Draube A., Beyer M., Schumer S., Thomas R.K., von Tresckow B., Koslowsky T.C., et al. Efficient activation of autologous tumor-specific T cells: a simple coculture technique of autologous dendritic cells compared to established cell fusion strategies in primary human colorectal carcinoma. J Immunother 2007, 30(4):359-369. 10.1097/CJI.0b013e31802bfefe.
27. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179(4):1109-1118.
28. Trefzer U., Walden P. Hybrid-cell vaccines for cancer immune therapy. Mol Biotechnol 2003, 25(1):63-69. 10.1385/MB:25:1:63.
29. Rubin I., Yarden Y. The basic biology of HER2. Ann Oncol 2001, 12(Suppl. 1):S3-8.
30. Britten C.M., Meyer R.G., Kreer T., Drexler I., Wolfel T., Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 2002, 259(1-2):95-110.
31. Tanimoto K., Muranski P., Miner S., Fujiwara H., Kajigaya S., Keyvanfar K., et al. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells. Cytotherapy 2014, 16(1):135-146. 10.1016/j.jcyt.2013.08.008.
32. Sundarasetty B.S., Singh V.K., Salguero G., Geffers R., Rickmann M., Macke L., et al. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. Hum Gene Ther 2013, 24(2):220-237. 10.1089/hum.2012.128.
33. Salguero G., Daenthanasanmak A., Munz C., Raykova A., Guzman C.A., Riese P., et al. Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol 2014, 192(10):4636-4647. 10.4049/jimmunol.1302887.
34. Trautmann L., Rimbert M., Echasserieau K., Saulquin X., Neveu B., Dechanet J., et al. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J Immunol 2005, 175(9):6123-6132.
35. Shu S., Zheng R., Lee W.T., Cohen P.A. Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. Crit Rev Immunol 2007, 27(5):463-483.
36. Gottfried E., Krieg R., Eichelberg C., Andreesen R., Mackensen A., Krause S.W. Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun 2002, 2:15.
37. Trevor K.T., Cover C., Ruiz Y.W., Akporiaye E.T., Hersh E.M., Landais D., et al. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 2004, 53(8):705-714. 10.1007/s00262-004-0512-1.
38. Pinho M., Bergami-Santos P., Barbuto J. T cell stimulation by dendritic cell-tumor cell hybrids is enhanced in the presence of free dendritic cells. J Immunother Cancer 2013, 1(Suppl. 1):P232. 10.1186/2051-1426-1-s1-p232.
39. Zhang Y., Luo W., Wang Y., Liu Y., Zheng L. Purified dendritic cell-tumor fusion hybrids supplemented with non-adherent dendritic cells fraction are superior activators of antitumor immunity. PLoS ONE 2014, 9(1):e86772. 10.1371/journal.pone.0086772.
40. Chaudhry A., Das S.R., Jameel S., George A., Bal V., Mayor S., et al. A two-pronged mechanism for HIV-1 Nef-mediated endocytosis of immune costimulatory molecules CD80 and CD86. Cell Host Microbe 2007, 1(1):37-49. 10.1016/j.chom.2007.01.001.
41. Esche C., Lokshin A., Shurin G.V., Gastman B.R., Rabinowich H., Watkins S.C., et al. Tumor's other immune targets: dendritic cells. J Leukoc Biol 1999, 66(2):336-344.
42. Pinzon-Charry A., Maxwell T., Lopez J.A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005, 83(5):451-461. 10.1111/j.1440-1711.2005.01371.x.
43. Xu F., Ye Y.J., Liu W., Kong M., He Y., Wang S. Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice. Scand J Gastroenterol 2010, 45(6):707-713. 10.3109/00365521003650180.
44. Chung D.J., Romano E., Pronschinske K.B., Shyer J.A., Mennecozzi M., St Angelo E.T., et al. Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy. J Transl Med 2013, 11:166. 10.1186/1479-5876-11-166.
45. Cao W., Lee S.H., Lu J. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem J 2005, 385(Pt 1):85-93. 10.1042/BJ20040741.
46. Bubenik J. Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep 2003, 10(6):2005-2008.
47. Fabre J.W. The allogeneic response and tumor immunity. Nat Med 2001, 7(6):649-652. 10.1038/89008.
48. Koido S., Hara E., Homma S., Torii A., Toyama Y., Kawahara H., et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 2005, 11(21):7891-7900. 10.1158/1078-0432.CCR-05-1330.
49. Ramos R.N., Chin L.S., Dos Santos A.P., Bergami-Santos P.C., Laginha F., Barbuto J.A. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. J Leukoc Biol 2012, 92(3):673-682. 10.1189/jlb.0112048.
50. Yasuda T., Kamigaki T., Kawasaki K., Nakamura T., Yamamoto M., Kanemitsu K., et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 2007, 56(7):1025-1036. 10.1007/s00262-006-0252-5.
51. Mori M., Beatty P.G., Graves M., Boucher K.M., Milford E.L. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997, 64(7):1017-1027.
52. Koido S., Gong J. Characterization of structure and direct antigen presentation by dendritic/tumor-fused cells as cancer vaccines. Anticancer Res 2013, 33(2):347-354.
53. Parkhurst M.R., DePan C., Riley J.P., Rosenberg S.A., Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003, 170(10):5317-5325.
54. Rodrigues E.G., Garofalo A.S., Travassos L.R. Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo. Cytokines Cell Mol Ther 2002, 7(3):107-116. 10.1080/13684730310000121.